Drug Trial Radar · NCT00605215
BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
Last checked: Nov 20, 2026Latest source record: Apr 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,331
Actual
Start
Apr 24, 2008
Primary completion
Jun 10, 2011
Study completion Jun 10, 2011
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
- Sponsor type
- Industry
- First posted
- Jan 30, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study aims to compare the effect of daily oral treatment of laquinimod capsules 0.6 milligrams (mg) with the effect of placebo capsules (capsules that contain no active medication) as well as with the effect of an existing Multiple Sclerosis (MS) injectable drug: Interferon β-1a (Avonex®).
Conditions
- Multiple Sclerosis
Interventions
LaquinimodDrug
Laquinimod will be administered per dose and schedule specified in the arm description.
PlaceboDrug
Placebo matching to laquinimod will be administered per schedule specified in the arm description.
Avonex®Drug
Avonex® will be administered per dose and schedule specified in the arm description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Rate of Confirmed RelapsesTime frame: Baseline up to Month 24
Locations
170 sites in 19 countries. Site status is shown where the registry gives one.
Teva Investigational Site 1267
Birmingham, Alabama
Teva Investigational Site 1237
Phoenix, Arizona
Teva Investigational Site 1252
Phoenix, Arizona
Teva Investigational Site 1279
Phoenix, Arizona
Teva Investigational Site 1276
Tucson, Arizona
Teva Investigational Site 1272
Pasadena, California
Teva Investigational Site 1238
Sacramento, California
Teva Investigational Site 1280
Aurora, Colorado
Teva Investigational Site 1255
Orlando, Florida
Teva Investigational Site 1282
Sarasota, Florida
Teva Investigational Site 1275
Atlanta, Georgia
Teva Investigational Site 1250
Peoria, Illinois
Teva Investigational Site 1260
Indianapolis, Indiana
Teva Investigational Site 1268
Lenexa, Kansas
Teva Investigational Site 1277
New Orleans, Louisiana
Teva Investigational Site 1263
Shreveport, Louisiana
Teva Investigational Site 1269
Baltimore, Maryland
Teva Investigational Site 1274
Grand Rapids, Michigan
Teva Investigational Site 1239
Lebanon, New Hampshire
Teva Investigational Site 1265
Teaneck, New Jersey
Teva Investigational Site 1273
Albany, New York
Teva Investigational Site 1264
Amherst, New York
Teva Investigational Site 1283
Cedarhurst, New York
Teva Investigational Site 1249
Raleigh, North Carolina
Teva Investigational Site 1262
Winston-Salem, North Carolina
Teva Investigational Site 1261
Akron, Ohio
Teva Investigational Site 1241
Canton, Ohio
Teva Investigational Site 1245
Cleveland, Ohio
Teva Investigational Site 1247
Columbus, Ohio
Teva Investigational Site 1244
Portland, Oregon
Teva Investigational Site 1258
Philadelphia, Pennsylvania
Teva Investigational Site 1281
Nashville, Tennessee
Teva Investigational Site 1284
San Antonio, Texas
Teva Investigational Site 1248
Richmond, Virginia
Teva Investigational Site 1270
Roanoke, Virginia
Teva Investigational Site 1253
Tacoma, Washington
Teva Investigational Site 5914
Pleven, Bulgaria
Teva Investigational Site 5915
Pleven, Bulgaria
Teva Investigational Site 5917
Plovdiv, Bulgaria
Teva Investigational Site 4212
Rousse, Bulgaria
Showing 40 of 170 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.